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Abstract. 
 
Spinal muscular atrophy (SMA) is character-
ized by degeneration of motor neurons of the spinal
cord associated with muscle paralysis and caused by
mutations of the survival motor neuron gene (
 
SMN
 
).
To determine whether 
 
SMN
 
 gene defect in skeletal
 
muscle might have a role in SMA pathogenesis, dele-
 
tion of murine 
 
SMN
 
 exon 7, the most frequent mutation
found in SMA, has been restricted to skeletal muscle by
using the 
 
Cre-loxP 
 
system. Mutant mice display ongoing
muscle necrosis with a dystrophic phenotype leading to
muscle paralysis and death. The dystrophic phenotype
is associated with elevated levels of creatine kinase ac-
tivity, Evans blue dye uptake into muscle ﬁbers, re-
duced amount of dystrophin and upregulation of utro-
phin expression suggesting a destabilization of the
sarcolemma components. The mutant mice will be a valu-
able model for elucidating the underlying mechanism.
Moreover, our results suggest a primary involvement of
skeletal muscle in human SMA, which may contribute to
motor defect in addition to muscle denervation caused
by the motor neuron degeneration. These data may
have important implications for the development of
therapeutic strategies in SMA.
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Introduction
 
Spinal muscular atrophy (SMA)
 
1 
 
is an autosomal recessive
neuromuscular disorder that represents a common genetic
cause of death in childhood (Munsat, 1991). SMA is char-
acterized by degeneration of motor neurons of the spinal
cord associated with muscle paralysis and atrophy. Muta-
 
tions of the survival motor neuron gene (
 
SMN
 
) are respon-
sible for SMA (Lefebvre et al., 1995). 
 
SMN
 
 is duplicated in
an inverted repeat in the same region of chromosome 5.
Homozygous deletion or conversion events of the 
 
SMN
 
exon 7 are the most frequent mutations found in SMA pa-
tients (95%) whereas the copy gene (
 
SMNc
 
) remains
present (Lefebvre et al., 1995; for review see Melki, 1997).
Full-length protein is almost exclusively produced by 
 
SMN
 
whereas the predominant form encoded by 
 
SMNc
 
 is lack-
ing the carboxy terminus through an alternative splicing of
exon 7 (Lefebvre et al., 1995). In contrast to the human,
the mouse 
 
SMN
 
 gene is not duplicated, which may explain
the fact that conventional knockout of the 
 
SMN
 
 gene re-
sults in embryonic lethality (Schrank et al., 1997; Frugier et
al., 2000; Hsieh-Li et al., 2000). The association of SMN
with spliceosomal components suggested that SMN has a
critical role in the cytoplasmic assembly of spliceosomal U
snRNPs and in the recycling of splicing factors after pre-
mRNA processing (Liu and Dreyfuss, 1996; Fischer et al.,
1997; Pellizzoni et al., 1998). However, the molecular con-
sequences of the 
 
SMN
 
 gene defect remain to be elucidated.
To gain insight into the pathogenesis of SMA and to cir-
cumvent the early lethality, several strategies have been
carried out leading to generation of mouse models of SMA
(Frugier et al., 2000; Hsieh-Li et al., 2000; Monani et al.,
2000). The 
 
Cre-LoxP
 
 recombination system of bacterio-
 
phage P1 has been used to direct deletion of the murine 
 
SMN
 
exon 7 to neurons but not to skeletal muscle (Sternberg
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and Hamilton, 1981; Sauer and Henderson, 1988; Frugier
et al., 2000). Mutant mice exhibit skeletal muscle denerva-
tion leading to muscle paralysis, a constant feature found
in human SMA, associated with morphological changes of
motor neurons (Frugier et al., 2000). These results pro-
vided evidence that motor neurons are targets of the gene
defect. To determine whether 
 
SMN
 
 gene defect in skeletal
muscle might have a role in SMA pathogenesis, deletion of
exon 7 restricted to skeletal muscle has been undertaken.
 
Materials and Methods
 
Generation of SMN Mutant Mice
 
Mice harboring 
 
SMN
 
 exon 7 flanked by two loxP sites (
 
SMN
 
F7
 
) were gen-
erated through homologous recombination in embryonic stem cells
(Frugier et al., 2000). Mouse lines carrying heterozygous deletion of 
 
SMN
 
exon 7 (
 
SMN
 
D
 
7/
 
1
 
) or expressing the 
 
Cre
 
 recombinase transgene driven by
the promoter of the human 
 
a
 
-skeletal actin gene were previously charac-
terized (
 
HSA-Cre79
 
; Miniou et al., 1999, Frugier et al., 2000). To genotype
mice, primers Ex7sou1 and GS8 were used to amplify either the wild-type
allele (435 bp), the 
 
SMN
 
F7
 
 allele (635 bp), or both (Frugier et al., 2000).
Detection of the 
 
SMN
 
D
 
7
 
 allele was performed by PCR amplification using
primers pHR5 and GS8 (Frugier et al., 2000). The transmission of the
 
HSA-Cre79
 
 transgene was confirmed by PCR using primers Cre1 and
Cre2 (Frugier et al., 2000). All animal procedures were performed in ac-
cordance with institutional guidelines.
 
Reverse Transcription (RT)-PCR
Amplification Analysis
 
Total RNA was extracted from freshly isolated tissues using the Trizol
procedure (GIBCO BRL). PCR amplification analysis of single strand
cDNA was performed using primers flanking 
 
SMN
 
 exon 7 (ex5sou2, 5
 
9
 
-
TGC TGG ATG CCC CCG TTC CCT TCA-3
 
9
 
 and ex8sou, 5
 
9
 
-GGC
ACG CTC TGC TGC TGA CTT AG-3
 
9
 
; Frugier et al., 2000) and reveals
 
SMN
 
 transcripts containing (350 bp) or lacking exon 7 (290 bp). Primers
ex5sou2 and ex7sou2 (5
 
9
 
-AAT TTG TAT GTG AGC ACT TTC CTT
CT-3
 
9
 
) were used to amplify 
 
SMN
 
 transcripts containing exon 7 (190 bp).
For semiquantitative PCR amplification analysis, aldolase A cDNA was
coamplified using primers 
 
aldo 1
 
 (5
 
9
 
-TAA GAA GGA TGG AGC CGA
CTT TG-3
 
9
 
) and 
 
aldo 600
 
 (5
 
9
 
-GCG AGG CTG TTG GCC AGG GCG
 
CG-3
 
9
 
) and used as internal control. After 20 cycles, reaction products
were removed and the remainder was submitted to 10 further cycles of
amplification. RT-PCR products were separated by agarose gel electro-
phoresis and labeled with ethidium bromide. Relative quantitation was
achieved by densitometric scanning (GS 710; Bio-Rad Laboratories).
 
Serum Level of Creatine Kinase Activity
 
Quantitative determination of creatine kinase activity of serum of control
(
 
SMN
 
F7/
 
1
 
) or mutant mice (
 
SMN
 
F7/
 
D
 
7
 
,
 
 HSA-Cre
 
) was measured using cre-
atine kinase (CK) reagent according to the manufacturer’s instructions
(Roche Diagnostics). Blood was collected by intracardiac puncture of anes-
thetized mice and the serum was stored at 
 
2
 
80
 
8
 
C before measurement.
 
Antibodies
 
Affinity-purified polyclonal antibodies against 
 
a
 
- and 
 
b
 
-sarcoglycan, 
 
b
 
-dys-
troglycan, and utrophin were previously characterized (Araishi et al.,
1999). An antiserum against the domain VI of the 
 
a
 
-2 chain of laminin was
described previously (Kuang et al., 1998). Monoclonal antibodies directed
against the COOH terminus, the NH
 
2
 
 terminus or the rod domain of dys-
trophin (MANDRA1 from Sigma-Aldrich; NCL-Dys3 or Dys1 from Novo-
castra, respectively), the 
 
g
 
-sarcoglycan (NCL-g-SARC; Novocastra), the
NH
 
2
 
 terminus of SMN (S55920; Transduction Laboratories), actin (Amer-
sham Pharmacia Biotech), 
 
b
 
-tubulin (Sigma-Aldrich), and antineurofila-
ment directed against the 160-kD isoform (Boehringer) were used. Poly-
clonal antibodies against murine collagen IV were purchased from AbCys.
 
Morphological and Immunofluorescence Analyses
 
Histology and histochemistry of skeletal muscle were performed on un-
fixed samples frozen in isopentane precooled in liquid nitrogen and trans-
verse sections of 8–10-
 
m
 
m thick were stained with hematoxylin and eosin
or treated for myosin ATPase reactions. To identify neuromuscular junc-
tions, acetylcholine receptors (AChR) were labeled with rhodamine-con-
jugated 
 
a
 
-bungarotoxin as previously described (Frugier et al., 2000).
For immunofluorescent analysis, 6-
 
m
 
m transverse frozen sections were
prepared from skeletal muscle or heart of control and mutant mice. Sec-
tions were fixed in cold acetone for 5 min. Sections were incubated with
antibodies diluted in 3% BSA in PBS for 1 h at room temperature. After
washing with 0.1% Tween 20 in PBS, sections were incubated with fluo-
rescein-conjugated anti–rabbit IgG (TAGO) for 1 h at room temperature.
For immunostaining of dystrophin, frozen sections were fixed with metha-
nol for 10 min and incubated in blocking solution containing 3% BSA, 3%
goat serum in PBS three times for 10 min each, and then with the
Figure 1. Motor defect and skele-
tal muscle morphology of control
and (SMNF7/D7, HSA-Cre) mice.
(A) Control littermate. (B) Note
the marked paralysis with abnor-
mal posture of the limbs and cy-
phosis of 4-wk-old (SMNF7/D7,
HSA-Cre) mice. (C–E) Hematox-
ylin and eosin staining of trans-
verse sections of gastrocnemius
from control littermate (C), 3-
(D), and 4- (E) wk-old (SMNF7/D7,
HSA-Cre) mice. Before the onset
of muscle paralysis (D), muscle
histology is similar to control skel-
etal muscle except the presence of
rare necrotic muscle fibers sur-
rounded by mononuclear cells
(indicated by arrow). After the
onset of muscle paralysis (E),
skeletal muscle histology revealed
necrotic fibers (filled arrow), re-
generating myocytes with central
nucleus (open arrow), variation in
fiber size and infiltration of con-
nective tissue. Bar, 35 mm. 
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MANDRA1 anti-dystrophin or NCL-DYS3. After washing in 0.1%
Tween 20/PBS, sections were incubated with Cy3-conjugated anti–mouse
antibodies (Jackson ImmunoResearch Laboratories) for 1 h at room tem-
perature. For double immunostaining of dystrophin and utrophin, sections
were incubated with anti-dystrophin revealed with Cy3-conjugated anti–
mouse antibodies as described above and then incubated with the poly-
clonal anti-utrophin antibodies, washed, and incubated with fluorescein-
conjugated anti–rabbit IgG. Sections were then mounted with Vectashield
mounting medium (Vector Laboratories) and observed under Zeiss Axio-
phot fluorescence microscope.
 
 
 
Toluidine blue staining of the spinal cord
as well as quantification of motor neuron number were performed as pre-
viously described (Frugier et al., 2000). For in toto immunostaining of
neuromuscular junctions, skeletal muscles have been directly fixed for 1 h
in 2% formaldehyde, and then incubated for 1 h in PBS (pH 7.4) contain-
ing 0.1 M glycine. Presynaptic motor nerve terminals have been stained
with monoclonal antibody directed against the 160-kD isoform of neu-
rofilament and AChR with rhodamine-conjugated 
 
a
 
-bungarotoxin. Motor
end plates have been labeled on whole mount preparations of teased mus-
cle fibers from intercostal, biceps brachii, and gastrocnemius and the
teased fibers have been mounted in Mowiol-glycerol.
To detect damage of muscle fibers, Evans blue dye (EBD, 10 mg/ml in
PBS; Sigma-Aldrich) was injected intraperitoneally into mice (0.1 ml/10 g
body weight). The mice were killed 12 h after injection and their muscles
were sectioned and fixed with methanol (10 min) and examined under a
fluorescence microscope. To correlate dystrophin with EBD staining,
fixed methanol sections from EBD-injected mice were treated with block-
ing solution (3% BSA, 3% goat serum in PBS) before incubation for 1 h
with the anti-dystrophin antibody (MANDRA1). Dystrophin labeling was
revealed using a fluorescein-conjugated anti–mouse IgG (Immunotech).
 
Western Blot Analysis
 
Frozen skeletal muscles including gastrocnemius and quadriceps from nine
mutant or control mice were crushed in liquid nitrogen using a mortar and
pestle. The pulverized muscle samples were transferred to 20 vol of SDS-
PAGE sample buffer (15% SDS, 75 mM Tris HCl, pH 6.8, 20% glycerol,
0.25% 2-mercaptoethanol, saturated bromophenol blue) supplemented
with protease inhibitor cocktail
 
 
 
(5 
 
m
 
l/100 mg of wet weight; Sigma-
Aldrich),
 
 
 
vortexed, and boiled for 3 min. Protein samples were size frac-
tionated on 4–7% polyacrylamide/SDS gradient gels. After electrophore-
sis for 45 min at 40 mA, the proteins were transferred to nitrocellulose
filter (Schleicher & Schuell) overnight at 50 V at 4
 
8
 
C. The membranes
were then blocked in 5% nonfat dry milk in PBS for 2 h at room tempera-
ture and incubated with antibodies against the COOH terminus of human
dystrophin (MANDRA1), the rod domain of dystrophin (NCL-DYS1),
the NH
 
2
 
 terminus of SMN, actin, 
 
b
 
-tubulin, 
 
a
 
-sarcoglycan, 
 
g
 
-sarcoglycan,
or utrophin. The membranes were washed in four changes of PBS, 0.05%
Tween 20, and incubated with anti–mouse or anti–rabbit IgG conjugated
to horseradish peroxydase and the immune complexes were revealed using
chemiluminescent detection reagents (Pierce Chemical Co.).
 
Results
 
Generation of Mutant Mice Carrying Deletion of SMN 
Exon 7 Directed to Skeletal Muscle
 
Through homologous recombination in embryonic stem
cells, mouse line carrying two loxP sites flanking 
 
SMN
 
exon 7 (
 
SMN
 
F7
 
) has been previously generated and a
strain homozygous for the 
 
SMN
 
F7
 
 allele has been estab-
lished (
 
SMN
 
F7/F7
 
; Frugier et al., 2000). To direct deletion
of 
 
SMN
 
 exon 7 to skeletal muscle, transgenic mouse line
expressing the Cre recombinase gene driven by the pro-
moter of the human 
 
a
 
-skeletal actin gene has been used
(
 
HSA-Cre79
 
; Miniou et al., 1999). Mice homozygous for
the 
 
SMN
 
F7
 
 allele (
 
SMN
 
F7/F7
 
) were crossed to mice carrying
an heterozygous deletion of 
 
SMN
 
 exon 7 (
 
SMN
 
D
 
7
 
; Frugier
et al., 2000) and expressing the 
 
HSA-Cre79
 
 transgene. 37
of 140 mice (26.4%) carried both 
 
HSA-Cre79
 
 recombinase
transgene and the 
 
SMN
 
F7/
 
D
 
7
 
 genotype (termed 
 
SMN
 
F7/
 
D
 
7
 
,
 
HSA-Cre
 
), as expected. Mutant mice carrying this geno-
type were indistinguishable from their control littermates
up to 3 wk of age. However, after 3 wk of age, (
 
SMN
 
F7/
 
D
 
7
 
,
HSA-Cre
 
) mutant mice of both sexes develop severe mus-
cle paralysis with reduced spontaneous and induced motor
activity and severe cyphosis (Fig. 1). Mutant mice exhibit
an extremely reduced life expectancy dying at a mean age
of 33 d (28–37, 
 
n
 
 
 
5 
 
18).
To determine whether the Cre-mediated activity led to
deletion of 
 
SMN
 
 exon 7 derived from the 
 
SMN
 
F7
 
 allele,
RT-PCR amplification analysis of RNA extracted from
skeletal muscle of mutant or control mice was performed
using primers flanking or including 
 
SMN
 
 exon 7, the tar-
geted DNA region. Semiquantitative RT-PCR analysis of
 
SMN
 
 revealed a slight reduction of the full-length tran-
script during the postnatal period of control mice (Fig. 2).
In mutant mice, a dramatic decrease of full-length SMN
transcript was observed and SMND7 transcript was the pre-
dominant form in skeletal muscle of mutant mice from
15 d of age (Fig. 2). The SMN transcript pattern of spinal
cord or heart of (SMNF7/D7, HSA-Cre) mutant mice was
similar to that of mice carrying the SMNF7/D7 genotype but
lacking the Cre recombinase transgene (data not shown).
Furthermore, Cre recombinase activity was specifically di-
rected to skeletal muscle as evidenced by the detection of
SMN exon 7 deletion in DNA extracted from skeletal
muscles but not from the other tissues including spinal
cord and sciatic nerve of mice carrying the (SMNF7/1,
HSA-Cre) genotype (Fig. 2). These data indicate that Cre-
mediated deletion of exon 7 was restricted to skeletal mus-
cle with a maximal efficiency after 10 d of age (Miniou et
al., 1999; and Fig. 2). Immunoblotting of proteins prepared
from skeletal muscle of mutant or control mice was per-
formed using a monoclonal antibody directed against the
NH2 terminus of the SMN protein. In control, the amount
of the SMN protein slightly decreases during the postnatal
period in accordance with the RNA pattern (Fig. 2). Dra-
matic reduction of SMN was observed in skeletal muscle
of 15-d-old mutant mice in agreement with the marked de-
crease of full-length SMN transcript (Fig. 2). The residual
amount of the SMN protein correlated with the low
amount of full-length SMN transcript resulting from in-
complete excision of SMN exon 7 (Fig. 2).
Marked Reduction of SMN Leads to Severe
Muscular Dystrophy
Hematoxylin and eosin staining of transverse sections of
several skeletal muscles including gastrocnemius, intercos-
tal, and biceps brachii from control or mutant mice before
or after the onset of muscle paralysis was evaluated at the
age of 3 or 4 wk, respectively. At 3 wk of age, the morphol-
ogy of skeletal muscle from mutant mice was similar to that
of control littermates except the presence of some rare ne-
crotic muscle fibers surrounded by mononuclear cell infil-
tration (Fig. 1). Surprisingly, a dramatic change of the his-
tological picture was noticed in 4-wk-old mutant mice after
the onset of muscle paralysis. The changes consisted of ex-
cessive variation in fiber size, infiltration of connective tis-
sue with mononuclear cells, evidence of muscle cell necro-
sis, and regenerating myocytes with large central nuclei.
The number of fibers with central nuclei was 9/389 (2.3%)
and 88/554 (15.8%) at 3- and 4-wk-old mutant mice, respec-The Journal of Cell Biology, Volume 152, 2001 1110
tively. In wild-type mice, the percentage of centrally placed
nuclei was 3/258 (1.1%). A qualitative comparison of fiber
type distribution assessed with myosin ATPase staining re-
vealed a predominance of type II muscle fibers in soleus
muscle of mutant mice as compared with wild-type mice
(data not shown). No endomysial fibrosis was noticed (Fig.
1 and data not shown). Any change was observed in heart
of mutant mice (data not shown).
To determine whether the muscular changes were associ-
ated with or due to a neurogenic process, the neuromuscu-
lar system was examined. Rhodamine-conjugated a-bunga-
rotoxin was used to label the AChR at the neuromuscular
junction on transverse sections of skeletal muscle. In 4-wk-
old mutant mice, AChR staining was concentrated at the
neuromuscular junction, an aspect similar to that of control
mice and no extrajunctional labeling was observed (Fig. 3).
Moreover, motor end plates labeled on whole mount prep-
arations of teased muscle fibers did not reveal any change
in presynaptic terminals, postsynaptic folds, or in the num-
ber of neuromuscular junctions of mutant mice (Fig. 3 and
Figure 2. Analysis of SMN and components of the DGC. (A) Semiquantitative RT-PCR amplification of SMN transcripts from skeletal
muscle using primers flanking exon 7 reveals transcripts containing (SMN FL) or lacking exon 7 (SMND7, first panel). Primers ex5sou2
and ex7sou2 were used to amplify SMN transcripts containing exon 7 only (SMN FL, second panel). Aldolase A cDNA was coamplified
and used as internal control (third panel). RT-PCR analysis reveals SMN FL transcript only in control (1/1, lane 2). In addition to the
full-length RT-PCR product (SMN FL), a shorter product corresponding to SMND7 transcript is detected in 1/SMND7 tissue (lane 1).
In mutant mice (MM, lanes 3–7), note the dramatic reduction of full-length product in skeletal muscle from 15 d of age (15 d., lane 5–7)
whereas the SMND7 is the predominant form. Note the slight decrease of SMN transcript during the postnatal period of control mice (1/1,
fourth panel). (B) Tissue specific deletion of the SMNF7 allele was demonstrated by PCR analysis of DNA extracted from a variety of
tissues of mice carrying the (SMNF7/1, HSA-Cre) genotype using primers PHR5 and GS8. A 450-bp fragment was successfully amplified
in skeletal muscles but not in the other tissues indicating the presence of Cre recombinase activity restricted to skeletal muscle (upper
panel). PCR amplification analysis using primers flanking SMN exon 4 was used as internal positive control (630 bp, lower panel;
Frugier et al., 2000). (C) Western blot analysis of proteins extracted from skeletal muscle using a monoclonal antibody directed against
the NH2 terminus of SMN. Note the marked reduction of SMN levels from 15-d-old mutant mice (MM, 15 d., lane 8–10) compared with
control (1/1, lanes 1–5). Incubation with monoclonal anti-actin antibody was used as internal control. (D and E) Western blot analysis
of proteins extracted from skeletal muscle using a monoclonal anti-dystrophin antibody (MANDRA1, D) and polyclonal antibodies
against utrophin (E). Note the reduction of dystrophin in 4-wk-old mice (SMNF7/D7, HSA-Cre, lanes 1–4) compared with control (1/1)
associated with an upregulation of utrophin expression (E). Actin was used as internal control. Relative quantitation was achieved by
densitometric scanning and the amount is indicated. MM, mutant mice; 1/1, wild type; SMNFL, full-length SMN transcript; SMND7,
SMN transcript lacking exon 7; d., postnatal day.Cifuentes-Diaz et al. SMN Exon 7 Deletion in Skeletal Muscle 1111
data not shown). A morphological analysis on transverse
semi-thin sections of spinal cord was performed on 4-wk-
old control and mutant mice using toluidine blue staining.
In mutant mice, the morphology of motor neurons was sim-
ilar to that of control mice (Fig. 3). Finally, quantification
of motor neuron number was performed at the lumbar
level of the spinal cord using double labeling of nuclei and
cytoplasm by DAPI and antibody specific to choline acetyl
transferase, an enzyme specific to cholinergic neurons, re-
spectively. At 4 wk of age, no significant loss of motor neu-
rons of the anterior horns was detected in mutant mice
(data not shown). These data strongly suggest that the mus-
cular changes found in mutant mice are not caused by or do
not lead to motor neuron changes.
Mutant Mice Display Destabilization of
the Sarcolemma
To test whether the muscular dystrophic phenotype was
associated with membrane damage of skeletal muscle, the
release of muscle enzyme into the circulating blood was
evaluated in mutant mice. (SMNF7/D7, HSA-Cre) mutant
mice exhibited serum CK activity approximately six times
Figure 3. Motor neuron mor-
phology and labeling of the
neuromuscular junctions in con-
trol (A, C, E, and E9) and
(SMNF7/D7, HSA-Cre) mice (B,
D, F, and F9). Toluidine blue
staining of transverse semithin
sections of spinal cord (A and
B) does not reveal any morpho-
logical changes of motor neu-
rons of mutant mice (B) com-
pared with control (A).
Labeling of AChR using rho-
damine-conjugated a-bungaro-
toxin on transverse sections of
skeletal muscle of control (C)
and mutant mice (D). AChRs
are concentrated at the neuro-
mucular junctions with their
characteristic curved staining in
both control and mutant mice.
In toto immunostaining of neu-
romuscular junctions on whole
mount preparations of teased muscle fibers from control (E and E9) and mutant mice (F and F9). Any changes of presynaptic termi-
nals labeled with neurofilament antibody or postsynaptic folds stained with rhodamine-conjugated a-bungarotoxin were observed in
mutant mice. Bars: (A, B, and E–F9) 25 mm; (C and D) 50 mm.
Figure 4. Vital staining with
EBD and immunofluorescence
analysis of dystrophin in skeletal
muscle of control (A, A9, and
A99) and mutant mice at 3 (B,
B9, and B99) and 4 wk of age (C,
C9, and C99). Dye inclusion was
not detected in control muscle
(A). Vital staining with EBD re-
veals muscle fibers in intercostal
muscles of 3- or 4-wk-old mu-
tant mice associated with the
lack of dystrophin staining at the
sarcolemma (arrows). Note the
uptake of the fluorescein-conju-
gated anti–mouse IgG antibody
in EBD positive muscle fibers
(B9). (A99, B99, and C99), phase
contrast. Bar, 35 mm.The Journal of Cell Biology, Volume 152, 2001 1112
higher (3,455 U/liter, n = 11) than control littermates of
the same age (SMNF7/1, 590 U/liter, n = 15). Sarcolemma
integrity was further examined by intraperitoneal injection
of EBD, a membrane impermeant molecule, in control
and mutant mice. No uptake of EBD into skeletal muscle
fibers of control mice was detected (Fig. 4). In contrast,
red EBD autofluorescence was observed in 4-wk-old mu-
tant mice. Fluorescence microscopic analysis revealed
EBD uptake into 1.9 and 4.4% of skeletal muscle fibers
from gastrocnemius and intercostal, respectively (Fig. 4).
Interestingly, EBD-positive fibers were also detected in
muscles of 3-wk-old mutant mice indicating that plasma
membrane defect occured before muscle paralysis and
marked histological changes (Fig. 4).
These data led to examine the components of the
dystrophin-glycoprotein complex (DGC) in (SMNF7/D7,
HSA-Cre) mutant mice. The immunofluorescence stain-
ing of dystrophin was either patchy or lacking on trans-
verse sections of skeletal muscle from mutant mice using
antibodies directed against either the NH2 or the COOH
terminus of dystrophin (Fig. 5). Muscle fibers lacking
dystrophin staining were scattered and observed in dif-
ferent muscles including gastrocnemius, intercostal or bi-
ceps brachii. EBD accumulation into muscle fibers corre-
lated with the lack of dystrophin staining (Fig. 4).
Nevertheless, numerous muscle fibers lacking dystrophin
did not display accumulation of EBD (Fig. 4). Dystro-
phin staining on sections of heart from mutant mice ap-
peared similar to that of control (data not shown). Im-
munofluorescence analysis of utrophin, the autosomal
homologue of dystrophin, was performed in control and
mutant mice. In 4-wk-old control mice, utrophin is con-
centrated at the neuromuscular junction, while a marked
extra-junctional labeling was observed in mutant mice of
the same age (Fig. 5). This observation could be related
to the lack of dystrophin in muscle fibers. To test this hy-
pothesis, double labeling experiment of utrophin and
dystrophin on transverse sections of skeletal muscle from
control or mutant mice was performed. In mutant mice,
sarcolemmal staining of utrophin was observed outside
the neuromuscular junctions of muscle fibers expressing
or lacking dystrophin (Fig. 5). These data suggest that
muscle fibers displaying an abnormal expression pattern
of utrophin correspond to regenerated fibers, which
would be expected to express higher levels of utrophin.
In mutant mice, a- and b-sarcoglycan and b-dystroglycan
staining was comparable to that of control levels al-
though immunofluorescent labeling was lacking in some
muscle fibers (Fig. 6). Finally, a-2 chain of laminin and
collagen IV, components of the basal lamina (Sanes,
1982), were present in muscle fibers of mutant mice with
an immunofluorescent staining similar to that of control
muscle (Fig. 6). To further examine the expression of the
DGC components, immunoblot analysis was performed
on muscle proteins prepared from control or mutant
mice. Although dystrophin was present with a size similar
to that of control, the level of dystrophin was reduced in
SMN mutant mice associated with an higher amount of
utrophin in accordance with the immunofluorescence
staining (Fig. 2). The amount of g-sarcoglycan was
slightly reduced while a-sarcoglycan is similar to control
levels (data not shown).
Discussion
Using the Cre-loxP system, we have developed mutant
mice in which deletion of SMN exon 7 has been restricted
to skeletal muscle in order to determine whether a defect
Figure 5. Immunofluorescent
staining of dystrophin (A and B)
and utrophin (C and D) on
transverse frozen sections of
skeletal muscle from control (A
and C) and (SMNF7/D7, HSA-
Cre) mice (B and D). The
MANDRA1 anti-dystrophin an-
tibody stains the sarcolemma of
muscle fibers from control
mouse tissue (A) although it
fails to detect the sarcolemma of
some muscle fibers from mutant
mice (B). In control mouse tis-
sue, the polyclonal antiutrophin
antibodies stain the neuromus-
cular junction only (C, arrow),
although a marked extrajunc-
tional labeling of sarcolemma is
observed in mutant mice (D).
Double immunostaining experi-
ment of dystrophin (E and F)
and utrophin (E9 and F9) on
transverse frozen sections of
skeletal muscle from control (E,
E9, and E99), and (SMNF7/D7, HSA-Cre) mice (F, F9, and F99). In mutant mouse, some muscle fibers lacking dystrophin sarcolemmal
staining (F, filled arrow) display an upregulation of the sarcolemmal staining of utrophin (F9), whereas in other muscle fibers the utro-
phin sarcolemmal staining is observed despite the expression of dystrophin at the plasma membrane (open arrow). (E99 and F99) merged
images. Bars: (A–D) 50 mm; (E–F99) 35 mm.Cifuentes-Diaz et al. SMN Exon 7 Deletion in Skeletal Muscle 1113
of SMN in skeletal muscle might have a role in SMA
pathogenesis. Cre-mediated deletion of SMN exon 7 in
skeletal muscle of (SMNF7/D7,  HSA-Cre) mice led to a
dramatic reduction of full-length SMN transcript, the
SMND7 transcript being the predominant form in mutant
mice from 15 d of age. Importantly, the marked reduc-
tion of the SMN protein correlated with that of full-
length SMN transcript suggesting that the protein en-
coded by SMND7 transcript is unstable in vivo. The
marked decrease of SMN leads to a severe phenotype
characterized by an onset of muscle paralysis after 3 wk
of age with a severe course leading to death at a mean
age of 33 d. Analysis of skeletal muscle histology before
or after the onset of muscle paralysis demonstrated that
mutant mice developed a progressive myopathy. Skeletal
muscle histology of 3-wk-old mutant mice showed a mor-
phology similar to that of control mice except some ne-
crotic muscle fibers surrounded by mononuclear cells.
After the onset of muscle paralysis, extensive mononu-
clear cell infiltration associated with necrotic fibers, vari-
ability of muscle fiber diameter and regenerating myo-
cytes with central nuclei were observed. The histological
changes were consistent with a progressive muscular dys-
trophy, which follows loss of SMN protein rather closely.
Elevated levels of CK activity and EBD uptake into mus-
cle fibers associated with an abnormal pattern of dys-
trophin expression suggest damage of the sarcolemma
whereas the basal lamina components are preserved.
Consistently, histological analysis and sarcolemmal stain-
ing of dystrophin revealed no change in heart of para-
lyzed mutant mice. These results are in accordance with
the absence or very weak Cre recombinase activity in
heart preventing cardiomyocytes from targeted disrup-
tion of SMN exon 7 (Miniou et al., 1999).
One striking observation was the phenotypic severity
of SMN mutant mice characterized by severe muscle de-
generation with extremely reduced life expectancy, while
mice knockout for genes encoding dystrophin, a- or
b-sarcoglycan develop a milder course of disease pheno-
type with life span usually not altered (Bulfield et al.,
1984; Duclos et al., 1998; Araishi et al., 1999; Durbeej et
al., 2000). These data indicate that sarcolemma destabili-
zation is not sufficient to explain muscle paralysis and
death in SMN mutant mice. In these mice, the low pro-
portion of myocytes with central nuclei (15.8%) suggests
a weak regenerating process in response to necrosis,
which may contribute to the progressive phenotype. In
addition, our data revealed additional features which al-
low SMN and DGC mutant mice to be distinguished (a)
the small percentage of muscle fibers with EBD accumu-
lation despite the lack of dystrophin in numerous muscle
fibers, (b) EBD muscle fibers are distributed singly in
SMN mutant mice as opposed to clustered in DGC mu-
tants, and (c) the absence or mild reduction of dystro-
phin-associated proteins in SMN mutant mice. These
data strongly suggest that the mechanism associated with
or leading to sarcolemma damage and necrosis in SMN
mutant mice is different from that resulting from primary
defect of dystrophin and will require further investiga-
tion. Despite recent advances in the knowledge of SMN
function, the cellular mechanism resulting in motor neu-
ron degeneration in SMA remained to be elucidated. The
present study revealed that SMN gene defect leads to a
plasma membrane damage and necrosis of skeletal mus-
cle fibers and it can be hypothesized that a similar mech-
anism is involved in motor neuron degeneration.
Importantly, this study revealed that skeletal muscle is
a target of the SMN gene defect and suggests that muscle
involvement contributes to the motor defect in the hu-
man SMA disease. Although muscle denervation is the
most prominent feature in human SMA, about one
fourth of patients affected with the mildest form of child-
hood SMA (type III or Kugelberg Welander disease) ex-
hibit a hypertrophy of the calves, a feature similar to
that observed in Duchenne or Becker muscular dystro-
phies, which are caused by mutations of the dystrophin
gene (Bouwsma and Vanwijngaarden, 1980). Histological
changes consisting of markedly hypertrophic fibers, ex-
cessive variations in fiber size, internal nuclei, and prolif-
erative interstitial connective tissue have been observed
in type III SMA patients associated with degenerative
Figure 6. Immunofluorescent staining of a-chain of laminin (A
and B), collagen IV (C and D), a-sarcoglycan (E and F),
b-sarcoglycan (G and H), and b-dystroglycan (I and J) on trans-
verse sections of skeletal muscle from control (A, C, E, G, and I)
and (SMNF7/D7, HSA-Cre) mice (B, D, F, H, and J). The immu-
nofluorescent staining of laminin and collagen IV is similar to
that of control whereas the labeling of a-sarcoglycan, b-sarcogly-
can, or b-dystroglycan is lacking in rare muscle fibers of mutant
mice (arrows). Bar, 50 mm.The Journal of Cell Biology, Volume 152, 2001 1114
changes including necrosis and high serum levels of CK
activity (Namba et al., 1970; Mastaglia and Walton,
1971). Since these changes are characteristic features of
primary myopathies, they can simulate muscular dystro-
phy (Kugelberg and Welander, 1956). Constitutive ab-
normality of SMA muscle has also been suggested using
an in vitro models (Henderson et al., 1987; Braun et al.,
1995). These clinical and in vitro data are consistent with
those found in mutant mice. Therefore, it will be of inter-
est to evaluate the presence of sarcolemma damage in
muscle biopsies from SMA patients.
Although deletion of SMN exon 7 directed to neurons
or skeletal muscle leads to severe muscle paralysis and
death, examination of the neuromuscular system re-
vealed several different features. In the “neuronal” mu-
tant, histological changes were consistent with muscle
denervation pattern with groups of atrophic muscle fi-
bers associated with extrajunctional expression of the
AChR and marked morphological changes of motor neu-
ron nuclei. In contrast, the “muscular” mutant displays a
muscular dystrophic phenotype characterized by the
presence of necrotic fibers, regenerating myocytes, and
extensive mononuclear cell infiltration. Cre-mediated de-
letion of SMN exon 7 in skeletal muscle but not in spinal
cord or nerve demonstrates that the dystrophic pheno-
type is caused by the lack of SMN exon 7 in skeletal mus-
cle only. Neither muscle denervation process nor mor-
phological changes of motor neurons have been noticed
in the “muscular” mutant. These results indicate that the
neuronal or muscular mutant mice display distinct phe-
notypes. Moreover, the present study revealed that the
muscular changes caused by the SMN gene mutation re-
stricted to skeletal muscle do not promote motor neuron
degeneration. Murine SMN gene targeting directed to
both neurons and skeletal muscle will allow to know
whether skeletal muscle involvement may have any effect
on the neurodegenerative process in SMA. Based on the
Cre-loxP system, targeted mutagenesis of SMN directed
to either neurons (Frugier et al., 2000) or skeletal muscle
(this study) leads to a degenerative process indicating
that both motor neurons and skeletal muscle are likely
involved in SMA pathogenesis. These data may have im-
portant implications for the development of therapeutic
strategies in SMA.
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